Yeast Infection Companies

Latest Yeast Infection Companies Updates:

Scynexis Their long-awaited first-in-class antifungal Brexafemme (ibrefungerp) secured European Marketing Authorization for both vaginal and vulvovaginal candidiasis in July 2023. Following its US approval in June 2022, Brexafemme's European launch strengthens Scynexis' market position.

Cidara Therapeutics Announced positive top-line data from their ReSTORE Phase 3 trial in December 2023, showcasing the efficacy and safety of rezafungin as a first-line treatment for candidemia and invasive candidiasis. Potential FDA approval could significantly bolster their presence in the market.

Evotec Partnered with Evolutions Therapeutics to develop novel antifungal treatments for recurrent vulvovaginal candidiasis (RVVC). Their combined expertise aims to bring faster and more effective solutions to this challenging area.

Astellas Initiated Phase 2b clinical trials for their investigational oral antifungal ASP2897 for treating both acute and RVVC. This innovative compound holds promise for expanding treatment options and improving adherence.

Meda Pharma Launched their OTC vaginal microbiome restoration product, Canesten BioBalance, in Europe. This probiotic-based product offers a non-antifungal approach for restoring vaginal health and preventing recurrent yeast infections.

Viome Expanded their personalized microbiome testing and supplement service to include support for vaginal health and yeast infection prevention. This personalized approach tailors probiotics and other supplements to individual needs for improved efficacy.

List of Yeast Infection Key companies in the market:

• Sanofi


• Astellas Pharma Inc


• Synmedic Laboratories


• Astra Zeneca


• Synmedic Laboratories


• Allergan


• Pfizer Inc


• Brundavan Laboratories


• Merck & Co., Inc


• Corden Pharma